Loading…

Antagonists of the kappa opioid receptor

The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress. Short-acting OPRK antagonists have been recently developed as...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2014-05, Vol.24 (9), p.2021-2032
Main Authors: Urbano, Mariangela, Guerrero, Miguel, Rosen, Hugh, Roberts, Edward
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress. Short-acting OPRK antagonists have been recently developed as a potential improvement over long-acting prototypic ligands including nor-BNI and JDTic. Remarkably the short-acting LY2456302 is undergoing phase II clinical trials for the augmentation of the antidepressant therapy in treatment-resistant depression. This Letter reviews relevant chemical and pharmacological advances in the identification and development of OPRK antagonists.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2014.03.040